source · text/markdown
source_f3f02346b9af457a
sha256 6b6bb988387655f0aaf0ca197615c7a5bb0ea95660d4b5dee153cb35ec46f8be
by researka:v2 · 2026-06-27 16:23:17.374923+04:00
# Adjacent Evidence Brief: Telomere Cancer Effects — full paper ## Abstract Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Telomere Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Telomere biology sits at the intersection of aging and oncology, where both shortened and lengthened telomere states have been implicated in tumor initiation, progression, and treatment response, motivating efforts to determine whether telomere-targeted metrics can serve as prognostic biomarkers or therapeutic entry points. We performed an AI-assisted structured evidence synthesis across 26 curated reference papers, with each included source audited for design, population, outcome class, and effect direction before integration. Across the corpus, the evidence supports a tiered interpretation: in survivorship and prognostic cohorts, shorter telomere length signals worse recurrence and mortality; in germline-causal and telomere-maintenance contexts, longer telomere length signals higher incident cancer risk; and the telomere-targeted anti-aging case remains biologically plausible but clinically unproven, with translation to marketing claims still premature. **Evidence-abstraction note.** The 26 retained reference papers are not 26 independent primary clinical trials: 26 are review, indirect, mechanistic, or registered-protocol source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence. ## Methods ### Review type and protocol This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-telomere_cancer_effects-v06-DAILY-2026-06-27T12-15-16Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-27. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `telomere cancer effects aging` - `telomere cancer effects older adults` - `telomere cancer effects randomized controlled trial` - `telomere aging` - `telomere older adults` - `telomere randomized controlled trial` - `cancer aging` - `cancer older adults` - `cancer randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses telomere cancer effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 194 records in the receipt-candidate union, 74 were classified as source candidates and 26 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 194 | | Classified source candidates | 74 | | No extractable claims | 41 | | None-only claim binding | 8 | | Mixed partial-or-none claim-binding candidates | 49 | | Partial-only claim-binding candidates | 19 | | Strict high-confidence sources | 3 | | Admitted final sources | 26 | Admission-bucket note: The funnel rows are audit categories, not an additive conservation table. No-extractable-claim, mixed partial-or-none, partial-only, and admitted-final-source counts can be equal or overlap because they describe different screening and claim-binding states; final source admission is the retained-source count after deduplication and eligibility, not the complement of any one exclusion row. ### Exclusion reasons - Exclusion accounting is captured in the source-admission funnel above: retrieval, deduplication, claim-binding, and strict high-confidence admission reduce source candidates to the retained source set. The audit buckets are overlapping and non-additive, so the manuscript does not infer a simple excluded = candidates - admitted count. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mechanism, mortality and survival); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Evidence Landscape Source directness breakdown: 0/26 retained sources directly address the stated topic and aging-relevant hard endpoints; 26/26 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. ### Source Classification Map - Sasmita 2025: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2. - Alhareeri 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Jaeger 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Liu 2026: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2. - Markozannes 2022: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2. - Li 2026: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2. - Davidson-Swinton 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Langsenlehner 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. Topic-fit rationale: Sources are retained only when they operationalize telomere cancer effects directly or provide adjacent/contextual boundary evidence for the same construct. 0/26 retained sources are classified as direct; adjacent, contextual, review-level, or mechanistic sources are reclassified as boundary evidence rather than used for broad efficacy claims. Representative source-fit checks: Sasmita 2025 (review; Mortality and Survival), Alhareeri 2020 (indirect; Contextual Adjacent Evidence), Jaeger 2024 (indirect; Contextual Adjacent Evidence), Liu 2026 (indirect; Dosing and Pharmacokinetics), Markozannes 2022 (review; Immune and Inflammation). Substantive evidence synthesis: The manifest includes 26 retained sources, 0 direct-source row(s), and receipt-level directional coding across negative=1, null=6, positive=2, unclear=17. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Representative source-level signals are: Sasmita 2025: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2; result=Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; finding=representative statistic P = 0.039; source-level statistic reported; claims=113; Alhareeri 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; finding=representative statistic p = 0.004; source-level statistic reported; claims=104; Jaeger 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; finding=representative statistic p = 0.01; source-level statistic reported; claims=90; Liu 2026: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2; result=The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; finding=representative statistic p < 0.05; source-level statistic reported; claims=74; Li 2026: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; result=Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; finding=representative statistic p < 0.05; source-level statistic reported; claims=38; Davidson-Swinton 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗; finding=representative statistic P < .0001; source-level statistic reported; claims=38; Langsenlehner 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Leukocyte telomere attrition following radiotherapy in prostate cancer: a prospective study; finding=representative statistic p < 0.001; source-level statistic reported; claims=37; Ha 2023: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2; result=Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective; finding=representative statistic P = .903; source-level statistic reported; claims=32. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating. ## Key Findings Key findings from source synthesis: - Sasmita 2025: Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2. - Alhareeri 2020: Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; representative statistic p = 0.004; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Jaeger 2024: A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Liu 2026: The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; representative statistic p < 0.05; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2. - Li 2026: Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; representative statistic p < 0.05; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2. Source-level findings by outcome class: - Contextual Adjacent Evidence: Alhareeri 2020 (Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; representative statistic p = 0.004; source-level statistic reported; direction=unclear; directness=indirect; tier=B2); Jaeger 2024 (A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; direction=unclear; directness=indirect; tier=B2); Li 2026 (Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; representative statistic p < 0.05; source-level statistic reported; direction=positive; directness=indirect; tier=B2). - Dosing and Pharmacokinetics: Liu 2026 (The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; representative statistic p < 0.05; source-level statistic reported; direction=negative; directness=indirect; tier=B2). - Frailty: Brouwers 2016 (The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters; representative statistic p=0.88; source-level statistic reported; direction=positive; directness=indirect; tier=B2). - Immune and Inflammation: Markozannes 2022 (Systematic review of Mendelian randomization studies on risk of cancer; 61 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=review; tier=B2). - Longevity: Liang 2024 (DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause; representative statistic p = 0.3; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Mechanism: Afolabi 2026 (Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and; 3 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=mechanistic; tier=C1). - Mortality and Survival: Sasmita 2025 (Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; direction=unclear; directness=review; tier=B2); Ha 2023 (Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective; representative statistic P = .903; source-level statistic reported; direction=unclear; directness=indirect; tier=B2); Sarkar 2026 (Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer; representative statistic p = 0.0005; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). Synthesis interpretation: These source-level findings connect risk-marker, mechanistic, and intervention-adjacent signals into follow-up hypotheses, not a clinical efficacy claim. Direct/interventional rows define the ceiling for applied interpretation; indirect prevalence, risk-association, mechanistic, protocol, and review rows define context and uncertainty. Representative coded source verdicts remain: Sasmita 2025: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2; result=Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; finding=representative statistic P = 0.039; source-level statistic reported; claims=113; Alhareeri 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; finding=representative statistic p = 0.004; source-level statistic reported; claims=104; Jaeger 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; finding=representative statistic p = 0.01; source-level statistic reported; claims=90; Liu 2026: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2; result=The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; finding=representative statistic p < 0.05; source-level statistic reported; claims=74. The bounded conclusion follows from source direction, outcome class, evidence tier, and directness rather than from source count alone. Publication-year note: citation years follow the manifest metadata; when DOI/PubMed dates differ, the source should be treated as bibliographic/in-press metadata and not used for year-specific claims. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Telomere Cancer Effects / Contextual Adjacent Evidence | n=18; claims=480 | significant source statistic in 15/18 sources; receipt-level direction coded unclear | 15 indirect; 3 review | limited corpus depth in this outcome class | | Telomere Cancer Effects / Mortality and Survival | n=3; claims=165 | significant source statistic in 3/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class | | Telomere Cancer Effects / Dosing and Pharmacokinetics | n=1; claims=74 | negative signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Frailty | n=1; claims=30 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Immune and Inflammation | n=1; claims=61 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Longevity | n=1; claims=20 | reported statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Mechanism | n=1; claims=3 | no extracted directional signal in 1/1 sources | 1 mechanistic | single-source slice; hypothesis-generating | This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate. ### Contextual Adjacent Evidence Outcomes Contextual Adjacent Evidence remains a separate Results slice for Telomere Cancer Effects (n=18; claims=480; significant source statistic in 15/18 sources; receipt-level direction coded unclear; 15 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Alhareeri 2020 (Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; representative statistic p = 0.004; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Jaeger 2024 (A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Li 2026 (Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; representative statistic p < 0.05; source-level statistic reported; direction=positive; directness=indirect; tier=B2). - Davidson-Swinton 2026 (Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗; representative statistic P < .0001; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction. ### Mortality and Survival Outcomes Mortality and Survival remains a separate Results slice for Telomere Cancer Effects (n=3; claims=165; significant source statistic in 3/3 sources; receipt-level direction coded unclear; 2 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Sasmita 2025 (Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; direction=unclear; directness=review; tier=B2). - Ha 2023 (Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective; representative statistic P = .903; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Sarkar 2026 (Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer; representative statistic p = 0.0005; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). ### Frailty Outcomes Frailty remains a separate Results slice for Telomere Cancer Effects (n=1; claims=30; positive signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Brouwers 2016 (The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters; representative statistic p=0.88; source-level statistic reported; direction=positive; directness=indirect; tier=B2). ### Immune and Inflammation Outcomes Immune and Inflammation remains a separate Results slice for Telomere Cancer Effects (n=1; claims=61; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Markozannes 2022 (Systematic review of Mendelian randomization studies on risk of cancer; 61 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=review; tier=B2). ### Longevity Outcomes Longevity remains a separate Results slice for Telomere Cancer Effects (n=1; claims=20; reported statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Liang 2024 (DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause; representative statistic p = 0.3; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). ### Dosing and Pharmacokinetics Outcomes Dosing and Pharmacokinetics remains a separate Results slice for Telomere Cancer Effects (n=1; claims=74; negative signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Liu 2026 (The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; representative statistic p < 0.05; source-level statistic reported; direction=negative; directness=indirect; tier=B2). ### Mechanism Outcomes Mechanism remains a separate Results slice for Telomere Cancer Effects (n=1; claims=3; no extracted directional signal in 1/1 sources; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Afolabi 2026 (Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and; 3 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=mechanistic; tier=C1). ## Limitations The principal limitation is evidence-role imbalance. The retained corpus contains no sources classified primarily as direct clinical evidence, 25 adjacent clinical sources, and 1 mechanistic or model-system source, which means causal interpretation depends on how much weight is assigned to each evidence tier. A second limitation is endpoint heterogeneity. Study-level signals span the contextual adjacent evidence and frailty outcome classes, the contextual adjacent evidence, immune and inflammation, mechanism outcome classes, the dosing and pharmacokinetics outcome class, and no dominant outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design. A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review. ## Conclusion For telomere cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 26 included sources on Telomere Cancer Effects across 7 outcome classes and 4 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 26 curated reference papers, the evidence base for Telomere Cancer Effects shows a context-dependent profile. Positive signals appear in: contextual other, frailty. Negative signals appear in: dosing pharmacokinetics. Null findings dominate: contextual other, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest unresolved contrast is the null vs positive between Chen 2023 and Li 2026 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap | | frailty | 0 | 1 | positive | direct interventional hard-endpoint gap | | immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 18 | null, positive, unclear | conflict-resolution gap | | mechanism | 0 | 1 | null | direct interventional hard-endpoint gap | | dosing and pharmacokinetics | 0 | 1 | negative | direct interventional hard-endpoint gap | | mortality and survival | 0 | 3 | unclear | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P2 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: positive | | P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P4 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 18 indirect sources; direction profile: null, positive, unclear | | P5 | mechanism: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | ### Next-Study Design Recommendation The next high-yield study for Telomere Cancer Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Sasmita 2025; tier=B2; directness=review; endpoint=mortality survival; direction=unclear; representative statistic=P = 0.001. - Alhareeri 2020; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001. - Jaeger 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.001. - Liu 2026; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=negative; representative statistic=P = 0.001. - Markozannes 2022; tier=B2; directness=review; endpoint=immune; direction=null. - Davidson-Swinton 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001. - Li 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001. - Langsenlehner 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Ha 2023; tier=B2; directness=indirect; endpoint=mortality survival; direction=unclear; representative statistic=P = 0.019. - Gil-Korilis 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001. ### Findings Map - Sasmita 2025: Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2; finding=representative statistic P = 0.039; source-level statistic reported. - Alhareeri 2020: Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.004; source-level statistic reported. - Jaeger 2024: A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.01; source-level statistic reported. - Liu 2026: The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality in cigarette smokers: the Multiethnic Cohort study: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2; finding=representative statistic p < 0.05; source-level statistic reported. - Markozannes 2022: Systematic review of Mendelian randomization studies on risk of cancer: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2; finding=61 extracted claim(s); receipt-level direction is the coded finding. - Li 2026: Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2; finding=representative statistic p < 0.05; source-level statistic reported. - Davidson-Swinton 2026: Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic P < .0001; source-level statistic reported. - Langsenlehner 2026: Leukocyte telomere attrition following radiotherapy in prostate cancer: a prospective study: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p < 0.001; source-level statistic reported. - Ha 2023: Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective Cohort Study: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2; finding=representative statistic P = .903; source-level statistic reported. - Gil-Korilis 2026: Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.041; source-level statistic reported. - Brouwers 2016: The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters: outcome=Frailty; direction=positive; directness=indirect; tier=B2; finding=representative statistic p=0.88; source-level statistic reported. - Cheng 2026: Integrative Analysis of Telomere‐Related Genes Reveals Prognostic Signatures in Laryngeal Cancer: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.0069; source-level statistic reported. - Liang 2024: DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause mortality: outcome=Longevity; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.3; source-level statistic reported. - Sarkar 2026: Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.0005; source-level statistic reported. - Bhat 2023: Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.0004; source-level statistic reported. - Brown 2026: SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic P < 0.001; source-level statistic reported. - Chen 2023: Association between genetically determined telomere length and health‐related outcomes: A systematic review and meta‐analysis of Mendelian randomization studies: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2; finding=representative statistic p < 0.05; source-level statistic reported. - Alqaisi 2026: Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies—A Scoping Review: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2; finding=13 extracted claim(s); receipt-level direction is the coded finding. - Wan 2023: Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic P < 0.001; source-level statistic reported. - Genetta 2026: ZEB1 Promotes Alternate Lengthening of Telomeres at Multiple Levels: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; finding=12 extracted claim(s); receipt-level direction is the coded finding. - Andreikos 2024: The Association between Telomere Length and Head and Neck Cancer Risk: A Systematic Review and Meta-Analysis: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2; finding=representative statistic p = 0.005; source-level statistic reported. - Song 2022: Association Between Telomere Length and Skin Cancer and Aging: A Mendelian Randomization Analysis: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p = 0.01; source-level statistic reported. - Aierken 2026: Integrative Bulk and Single-Cell Transcriptome Profiling of Telomere-Related Genes Reveals a Robust Prognostic Signature and Immunotherapeutic Landscape in Neuroblastoma: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic P < 0.05; source-level statistic reported. - Gui 2025: Telomere-protecting protein 1 promotes gastric cancer cell metastasis via enhancing endoplasmic reticulum stress: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; finding=7 extracted claim(s); receipt-level direction is the coded finding. - Afolabi 2026: Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and therapeutic targeting: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1; finding=3 extracted claim(s); receipt-level direction is the coded finding. - Xu 2024: Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic P = 0.036; source-level statistic reported. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 4 null vs positive: Chen 2023 vs Li 2026; Li 2026 (positive on contextual other) vs Chen 2023 (null on contextual other) — partial conflict - Severity 4 null vs positive: Gui 2025 vs Li 2026; Li 2026 (positive on contextual other) vs Gui 2025 (null on contextual other) — partial conflict - Severity 4 null vs positive: Genetta 2026 vs Li 2026; Li 2026 (positive on contextual other) vs Genetta 2026 (null on contextual other) — partial conflict - Severity 4 null vs positive: Alqaisi 2026 vs Li 2026; Li 2026 (positive on contextual other) vs Alqaisi 2026 (null on contextual other) — partial conflict ## References - **Sasmita 2025.** _Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis._ Exploration of Targeted Anti-tumor Therapy, 2025. DOI: 10.37349/etat.2025.1002289. PMID: 40061142. - **Alhareeri 2020.** _Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study._ Breast Cancer Research : BCR, 2020. DOI: 10.1186/s13058-020-01368-6. PMID: 33276807. - **Jaeger 2024.** _A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study._ Nutrients, 2024. DOI: 10.3390/nu16172963. PMID: 39275278. - **Liu 2026.** _The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality in cigarette smokers: the Multiethnic Cohort study._ Clinical Epigenetics, 2026. DOI: 10.1186/s13148-026-02137-6. PMID: 42021368. - **Markozannes 2022.** _Systematic review of Mendelian randomization studies on risk of cancer._ BMC Medicine, 2022. DOI: 10.1186/s12916-022-02246-y. PMID: 35105367. - **Li 2026.** _Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk._ NPJ Aging, 2026. DOI: 10.1038/s41514-026-00352-2. PMID: 41776185. - **Davidson-Swinton 2026.** _Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗._ Blood, 2026. DOI: 10.1182/blood.2025031287. PMID: 41564438. - **Langsenlehner 2026.** _Leukocyte telomere attrition following radiotherapy in prostate cancer: a prospective study._ Scientific Reports, 2026. DOI: 10.1038/s41598-026-36205-x. PMID: 41565875. - **Ha 2023.** _Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective Cohort Study._ Integrative Cancer Therapies, 2023. DOI: 10.1177/15347354231154267. PMID: 37615075. - **Gil-Korilis 2026.** _Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort._ Molecular Medicine, 2026. DOI: 10.1186/s10020-026-01423-6. PMID: 41721457. - **Brouwers 2016.** _The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters._ Oncotarget, 2016. DOI: 10.18632/oncotarget.8796. PMID: 27102154. - **Cheng 2026.** _Integrative Analysis of Telomere‐Related Genes Reveals Prognostic Signatures in Laryngeal Cancer._ International Journal of Genomics, 2026. DOI: 10.1155/ijog/5301600. PMID: 41959623. - **Liang 2024.** _DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause mortality._ Aging Cell, 2024. DOI: 10.1111/acel.14174. PMID: 38629454. - **Sarkar 2026.** _Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer._ Cancers, 2026. DOI: 10.3390/cancers18030490. PMID: 41681962. - **Bhat 2023.** _Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India._ BMC Cancer, 2023. DOI: 10.1186/s12885-023-11387-z. PMID: 37718447. - **Brown 2026.** _SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres._ Neuro-Oncology, 2026. DOI: 10.1093/neuonc/noaf300. PMID: 41520142. - **Chen 2023.** _Association between genetically determined telomere length and health‐related outcomes: A systematic review and meta‐analysis of Mendelian randomization studies._ Aging Cell, 2023. DOI: 10.1111/acel.13874. PMID: 37232505. - **Alqaisi 2026.** _Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies—A Scoping Review._ Current Oncology, 2026. DOI: 10.3390/curroncol33020074. PMID: 41744838. - **Wan 2023.** _Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer._ PLOS ONE, 2023. DOI: 10.1371/journal.pone.0286219. PMID: 37352282. - **Genetta 2026.** _ZEB1 Promotes Alternate Lengthening of Telomeres at Multiple Levels._ Cancers, 2026. DOI: 10.3390/cancers18030499. PMID: 41681971. - **Andreikos 2024.** _The Association between Telomere Length and Head and Neck Cancer Risk: A Systematic Review and Meta-Analysis._ International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25169000. PMID: 39201686. - **Song 2022.** _Association Between Telomere Length and Skin Cancer and Aging: A Mendelian Randomization Analysis._ Frontiers in Genetics, 2022. DOI: 10.3389/fgene.2022.931785. PMID: 35903361. - **Aierken 2026.** _Integrative Bulk and Single-Cell Transcriptome Profiling of Telomere-Related Genes Reveals a Robust Prognostic Signature and Immunotherapeutic Landscape in Neuroblastoma._ Journal of Cancer, 2026. DOI: 10.7150/jca.129718. PMID: 42179790. - **Gui 2025.** _Telomere-protecting protein 1 promotes gastric cancer cell metastasis via enhancing endoplasmic reticulum stress._ The Journal of Biological Chemistry, 2025. DOI: 10.1016/j.jbc.2025.110998. PMID: 41338460. - **Afolabi 2026.** _Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and therapeutic targeting._ Frontiers in Cell and Developmental Biology, 2026. DOI: 10.3389/fcell.2026.1797677. PMID: 42317265. - **Xu 2024.** _Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer._ Frontiers in Immunology, 2024. DOI: 10.3389/fimmu.2024.1452946. PMID: 39355254. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "e95bf0e4-433d-4924-bd34-c19b19a2234f",
"title": "Adjacent Evidence Brief: Telomere Cancer Effects \u2014 full paper"
}